Filtered By:
Cancer: Leukemia
Therapy: Cancer Therapy
This page shows you your search results in order of date.
Order by Relevance | Date
Total 366 results found since Jan 2013.
Geographic Disparity of Outcome in Patients With Cancer Over Decades: The Surveillance, Epidemiology, and End Results
CONCLUSIONS: Significant disparities in cancer care exist among geographic locations. Geographic differences in survival appear more prominent when highly effective therapies are available.PMID:37690903 | DOI:10.1016/j.clml.2023.08.001
Source: Clinical Lymphoma and Myeloma - September 10, 2023 Category: Cancer & Oncology Authors: Koji Sasaki Kiyomi Morita Hagop Kantarjian Guillermo Garcia-Manero Elias Jabbour Farhad Ravandi Marina Konopleva Gautam Borthakur William Wierda Naval Daver Koichi Takahashi Courtney DiNardo Guillermo Montalban Bravo Ghayas C Issa Sherry A Pierce Kelly A Source Type: research
Dual role of autophagy for advancements from conventional to new delivery systems in cancer
Biochim Biophys Acta Gen Subj. 2023 Jul 26:130430. doi: 10.1016/j.bbagen.2023.130430. Online ahead of print.ABSTRACTAutophagy, a programmed cell-lysis mechanism, holds significant promise in the prevention and treatment of a wide range of conditions, including cancer, Alzheimer's, and Parkinson's disease. The successful utilization of autophagy modulation for therapeutic purposes hinges upon accurately determining the role of autophagy in disease progression, whether it acts as a cytotoxic or cytoprotective factor. This critical knowledge empowers scientists to effectively manipulate tumor sensitivity to anti-cancer therap...
Source: Biochimica et Biophysica Acta - July 28, 2023 Category: Biochemistry Authors: Parth Mehta Pravin Shende Source Type: research
A multitier virtual screening study of phytoconstituents as Myeloid Cell Leukemias 1 inhibitors
In this study, we aim to search for compounds that target the critical binding site of MCL1 from phytoconstituent library from the IMPPAT database. To accomplish this, a multitier virtual screening approach involving molecular docking and molecular dynamics simulations (MDS) were used to evaluate their suitability for the receptor. Notably, certain screened phytoconstituents have appreciable docking scores and stable interactions toward the binding pocket of MCL1. The screened compounds underwent ADMET and bioactivity analysis to establish their anticancer properties. One phytoconstituent, Isopongaflavone, was identified t...
Source: Cancer Control - July 7, 2023 Category: Cancer & Oncology Authors: Wenjun Liu Mohammad Khalid Shadma Wahab Mohd Faizan Siddiqui Shaheer Hasan Khan Mohd Sadiq Zeenat Khatoon Source Type: research
Dermatologic complications in transplantation and cellular therapy for acute leukemia
Best Pract Res Clin Haematol. 2023 Jun;36(2):101464. doi: 10.1016/j.beha.2023.101464. Epub 2023 Apr 6.ABSTRACTAdoptive cellular immunotherapy, mainly hematopoietic stem cell transplant and CAR-T cell therapy have revolutionized treatment of patients with acute leukemia. Indications and inclusion criteria for these treatments have expanded in recent years. While these therapies are associated with significant improvements in disease response and overall survival, patients may experience adverse events from associated chemotherapy conditioning, engraftment, cytokine storm, supportive medications, and post-transplant maintena...
Source: Cell Research - June 23, 2023 Category: Cytology Authors: Shahab Babakoohi Stephanie L Gu Hamid Ehsan Alina Markova Source Type: research
Research Strategy for the Development of a Quality-of-Life Decision-Making Model for Older Patients With Acute Myeloid Leukemia
J Adv Pract Oncol. 2023 May;14(4):272-283. doi: 10.6004/jadpro.2023.14.4.2. Epub 2023 May 1.ABSTRACTAcute myeloid leukemia (AML) is a deadly cancer, especially for patients over 60 years of age who face the dilemma of choosing the best treatment during a time of crisis. Current research in the older AML population is focused on survival without addressing quality of life (QOL). Survival and QOL data are essential for patients to decide which treatment best aligns with their goals, whether for survival or improved QOL. Research aims: The aims of this study are to: (1) Describe differences in QOL among newly diagnosed older ...
Source: Adv Data - June 14, 2023 Category: Epidemiology Authors: Sara M Tinsley-Vance Source Type: research
Discovery of new tetrahydroisoquinolines as potent and selective LSD1 inhibitors for the treatment of MLL-rearranged leukemia
Eur J Med Chem. 2023 May 25;257:115516. doi: 10.1016/j.ejmech.2023.115516. Online ahead of print.ABSTRACTHistone lysine-specific demethylase 1 (LSD1) is a promising target for cancer therapy. Here, we performed the design, synthesis, and extensive structure-activity relationship (SAR) studies based on our previously discovered natural LSD1 inhibitor, higenamine. We found that the tetracyclic tetrahydroisoquinoline FY-21 is a potent and selective inhibitor of LSD1 (IC50 = 340 nM). FY-21 inhibited leukemia cell proliferation and colony formation and increased the level of p53 expression. Meanwhile, FY-21 reduced the mRNA lev...
Source: European Journal of Medicinal Chemistry - May 31, 2023 Category: Chemistry Authors: Chao Yang Yuan Fang Yaxuan Hu Tiantian Tian Guochao Liao Source Type: research
Arsenic trioxide-induced cytotoxicity in A549 cells: The role of necroptosis
CONCLUSIONS: The A549 cells, after 48 h exposure to ATO at 50 and 100 μM, induces apoptosis and necroptosis. Due to the reduced expression of MLKL, it can be concluded that ATO is probably effective in the metastatic stage of cancer cells.PMID:37230480 | DOI:10.1055/a-2076-3246
Source: Cancer Control - May 25, 2023 Category: Cancer & Oncology Authors: Maryam Jamil Afshin Mohammadi-Bardbori Omid Safa Amin Reza Nikpoor Azizollah Bakhtari Mahnoosh Mokhtarinejad Saghar Naybandi Zadeh Amir Shadboorestan Mahmoud Omidi Source Type: research
Humoral Immunity After COVID-19 Vaccination in Chronic Lymphocytic Leukemia and Other Indolent Lymphomas: A Single-Center Observational Study
CONCLUSION: Antibody response is lower in patients with indolent lymphomas compared to the general population. Lower Ab seropositivity was found in patients with a history of anti-leukemic agent therapy or those immunized with Pfizer vaccine. This data suggests that Moderna vaccination may confer a greater degree of immunity against SARS-CoV-2 in patients with indolent lymphomas.PMID:37141401 | DOI:10.1093/oncolo/oyad121
Source: The Oncologist - May 4, 2023 Category: Cancer & Oncology Authors: Peter G Doukas Frederique St Pierre Reem Karmali Xinlei Mi Jennifer Boyer Mariana Nieves Michael G Ison Jane N Winter Leo I Gordon Shuo Ma Source Type: research
